Briefing: Advocacy wins & policy changes 2016-2020

Policy and advocacy   |   1 January 2021 

Share






Copied


As we embark on our new MSI 2030 strategy, we want to​​ share the advocacy results we achieved under our previous strategy ‘Scaling-Up Excellence’.

​Under the Scaling-Up Excellence​ strategy (2016-2020) our country programmes have contributed to securing 56 policy, law, regulation and financing changes. This list illustrates the evolution of advocacy in our organisation, led by the committed and determined advocacy focal points across our programmes. It demonstrates the power of advocacy and partnerships in creating a more enabling environment for safe abortion and contraception, and highlights MSI Reproductive Choice’s unique contribution in bringing the evidence of service provision to inform and influence policy and the strategic use of partnerships to engage with decision makers to drive change to increase access.

Under Scaling-Up Excellence we have seen a growth in our capacity and confidence to engage in advocacy. We have also seen the context for sexual and reproductive health and rights evolving, more countries have adopted regulation and quality standards in service delivery, but significant legal and financial barriers remain.

With our new strategy, we are looking forward to building on these successes to address the long term challenging and structural barriers to achieving universal access to SRHR. ​


Share






Copied

Related posts

Story


1 January 2021   |   2 min read

Every Stage of Woman: Providing Advice and Care throughout women’s lives

Expanding MSI clinical offerings to ensure women feel supported and cared for from menstruation to menopause.

Research


1 January 2021

How we’re engaging community leaders to expand access to reproductive choice

Insights from MSI’s work with community leaders in West Africa.

Story


1 January 2021   |   2 min read

Shifting social norms to empower choice

The role of social norms programming in making reproductive choice a reality for all.